Metraipolis › archive › dc_74bfd73448b7

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis — Europe PMC PMID:37788264

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/37788264
DOI
10.1371/journal.pone.0292231
License (as archived)
CC0-1.0
Archived
2026-10-07T12:01:28.221Z
SHA-256 of the archived text
6c80a001f648d2525e8452d27e334eb7f6e645ac6168edbc6a5e26d5c623a5b1
Stable URL of this page
https://metraipolis.com/documento/dc_74bfd73448b7

How to cite

Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis — Europe PMC PMID:37788264 — Europe PMC (en), https://europepmc.org/article/MED/37788264 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_74bfd73448b7 (Metraipolis archive dc_74bfd73448b7, sha256 6c80a001f648d2525e8452d27e334eb7f6e645ac6168edbc6a5e26d5c623a5b1)
BibTeX
@misc{dc74bfd73448b7,
  title = {Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis — Europe PMC PMID:37788264},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37788264},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_74bfd73448b7; sha256 6c80a001f648d2525e8452d27e334eb7f6e645ac6168edbc6a5e26d5c623a5b1},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37788264. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Biosimilars are increasingly available for the treatment of many serious disorders, however some concerns persist about switching a patient to a biosimilar whose condition is stable while on the reference biologic. Randomized controlled studies and extension studies with a switch treatment period (STP) to or from a biosimilar and its reference biologic were identified from publicly available information maintained by the U.S. Food and Drug Administration (FDA). These findings were augmented with data from peer reviewed publications containing information not captured in FDA reviews. Forty-four STPs were identified from 31 unique studies for 21 different biosimilars. Data were extracted and synthesized following PRISMA guidelines. Meta-analysis was conducted to estimate the overall risk difference across studies. A total of 5,252 patients who were switched to or from a biosimilar and its reference biologic were identified. Safety data including deaths, serious adverse events, and treatment discontinuation showed an overall risk difference (95% CI) of -0.00 (-0.00, 0.00), 0.00 (-0.01, 0.01), -0.00 (-0.01, 0.00) across STPs, respectively. Immunogenicity data showed similar incidence of anti-drug antibodies and neutralizing antibodies in patients within a STP who were switched to or from a biosimilar to its reference biologic and patients who were not switched. Immune related adverse events such as anaphylaxis, hypersensitivity reactions, and injections site reactions were similar in switched and non-switched patients. This first systematic review using statistical methods to address the risk of switching patients between reference biologics and biosimilars finds no difference in the safety profiles or immunogenicity rates in patients who were switched and those who remained on a reference biologic or a biosimilar.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-10-03).
Identificativi: PMID 37788264 · PMCID PMC10547155 · DOI 10.1371/journal.pone.0292231.
Descrittori MeSH principali: Anaphylaxis; Biosimilar Pharmaceuticals.
Pagina: https://europepmc.org/article/MED/37788264 — https://doi.org/10.1371/journal.pone.0292231. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:31:06.961Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.